Does age really matter? Radiotherapy in elderly patients with glioblastoma, the Munich experience
Abstract Background Glioblastoma is usually diagnosed around the age of 60–70 years. Patients older than 65 years are frequently described as “elderly”. Several trials with monotherapy have established treatment regimens that offer therapies with reduced side effects but reduced efficacy. We analyse...
Main Authors: | Christoph Straube, Hagen Scherb, Jens Gempt, Stefanie Bette, Claus Zimmer, Friederike Schmidt-Graf, Jürgen Schlegel, Bernhard Meyer, Stephanie E. Combs |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-04-01
|
Series: | Radiation Oncology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13014-017-0809-9 |
Similar Items
-
Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma
by: Miyuki Uno, et al.
Published: (2011-01-01) -
Prognostic Significance of MGMT Promoter Methylation in Patients with Glioblastoma Undergoing Surgical Intervention: A Retrospective Study in Northeastern Iran
by: Kazem Anvari, et al.
Published: (2018-07-01) -
A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide
by: Rui-Chao Chai, et al.
Published: (2019-09-01) -
Prognostic genetic markers in malignant gliomas
by: Ralf Ketter, et al.
Published: (2010-12-01) -
Influence of Intratumor Heterogeneity on the Predictivity of MGMT Gene Promoter Methylation Status in Glioblastoma
by: Giovanni Brigliadori, et al.
Published: (2020-10-01)